Intravenous ArtesunateObservational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants

Primary outcome measure

• Number of pregnant females with high blood pressure [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with severe nausea [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with vomiting [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with dehydration [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with diabetes (newly occurring) [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with obesity/marked weight gain [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with anemia (newly occurring) [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with kidney or bladder infections [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with vaginal bleeding [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with abruptio placenta [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with placenta previa [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with premature rupture of membranes [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with preterm labor [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with ectopic pregnancy [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with molar pregnancy [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females who died [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with spontaneous abortions/miscarriage [ Time Frame: Up to 20 weeks ]
• Number of pregnant females with elective terminations [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of fetal deaths/stillbirths [ Time Frame: From 20 weeks to study completion ]
• Number of premature live births (<37 weeks) [ Time Frame: Up to 37 weeks ]
• Number pregnant females with with live term births [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of pregnant females with normal vaginal delivery or C-section [ Time Frame: Through study completion, an average of 40 weeks ]
• Number of newborns with low birth weight (<2500 grams) [ Time Frame: At birth ]
• Number of newborns with heart and circulation defects [ Time Frame: At birth ]
• Number of newborns with genital and urinary tract defects [ Time Frame: At birth ]
• Number of newborns with nervous system and eye defects [ Time Frame: At birth ]
• Number of newborns with Club foot [ Time Frame: At birth ]
• Neonate mean body weight (kg) [ Time Frame: 1 month ]
• Infant mean body weight (kg) [ Time Frame: 12 months ]
• Number of infants who sit unattended or without support [ Time Frame: 12 months ]
• Number of infants who pick up small objects with thumb-finger grasp [ Time Frame: 12 months ]
• Number of infants who say "Dada" or "Mama" nonspecifically [ Time Frame: 12 months ]
• Number of infants who look for dropped objects or objects hidden by parents [ Time Frame: 12 months ]
• Neonate mean body length (cm) [ Time Frame: 1 month ]
• Neonate mean head circumference (cm) [ Time Frame: 1 month ]
• Infant mean recumbent weight (kg) [ Time Frame: 12 months ]
• Infant mean weight-for-length ratio (kg/cm) [ Time Frame: 12 months ]